Advances in medical treatment of breast cancer in 2022

Jingtong Zhai; Yun Wu; Fei Ma; Virginia Kaklamani; Binghe Xu

doi:10.1002/cai2.46

Advances in medical treatment of breast cancer in 2022

Jingtong Zhai, Yun Wu, Fei Ma, Virginia Kaklamani, Binghe Xu

Producción científica: Review article › revisión exhaustiva

21 Citas (Scopus)

Resumen

Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.

Idioma original	English (US)
Páginas (desde-hasta)	1-17
Número de páginas	17
Publicación	Cancer Innovation
Volumen	2
N.º	1
DOI	https://doi.org/10.1002/cai2.46
Estado	Published - feb 2023
Publicado de forma externa	Sí

ASJC Scopus subject areas

Oncology
Drug Discovery
Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Cancer Research
Pharmacology (medical)

Acceder al documento

10.1002/cai2.46

Otros archivos y enlaces

Citar esto

@article{a020211969a74f6fad0ccc113b7f1f29,

title = "Advances in medical treatment of breast cancer in 2022",

abstract = "Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.",

keywords = "breast cancer, chemotherapy, endocrine therapy, immunotherapy, targeted therapy",

author = "Jingtong Zhai and Yun Wu and Fei Ma and Virginia Kaklamani and Binghe Xu",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Cancer Innovation published by John Wiley & Sons Ltd on behalf of Tsinghua University Press.",

year = "2023",

month = feb,

doi = "10.1002/cai2.46",

language = "English (US)",

volume = "2",

pages = "1--17",

journal = "Cancer Innovation",

issn = "2770-9191",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Advances in medical treatment of breast cancer in 2022

AU - Zhai, Jingtong

AU - Wu, Yun

AU - Ma, Fei

AU - Kaklamani, Virginia

AU - Xu, Binghe

PY - 2023/2

Y1 - 2023/2

N2 - Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.

AB - Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.

KW - breast cancer

KW - chemotherapy

KW - endocrine therapy

KW - immunotherapy

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85148619086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148619086&partnerID=8YFLogxK

U2 - 10.1002/cai2.46

DO - 10.1002/cai2.46

M3 - Review article

C2 - 38090370

AN - SCOPUS:85148619086

SN - 2770-9191

VL - 2

SP - 1

EP - 17

JO - Cancer Innovation

JF - Cancer Innovation

IS - 1

ER -

Advances in medical treatment of breast cancer in 2022

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto